权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Molecular/histologic classification of DClS as predictors of recurrence & survival

DClS 的分子/组织学分类作为复发的预测因素

基本信息

批准号：
8715709
负责人：
Donald Lee Weaver
金额：
$ 17.15万
依托单位：
UNIVERSITY OF VERMONT & ST AGRIC COLLEGE
依托单位国家：
美国
项目类别：
财政年份：
2014
资助国家：
美国
起止时间：
2014-06-01 至 2016-05-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/8715709
关键词：
Agreement Algorithms Basic Science Biological Markers Biology Biopsy Breast Breast Cancer Detection Breast Diseases Carcinoma Categories Cessation of life Chromosome abnormality Classification Congenital Abnormality Data Diagnosis Diagnostic Disease Ductal Breast Hyperplasia Event Excision Frequencies Goals Histologic In Situ Lesion Indolent Intervention Investigation Lead Life Malignant - descriptor Malignant Neoplasms Mammography Mastectomy Methods Minority Molecular Molecular Abnormality Molecular Genetics Molecular Probes Mutation Noninfiltrating Intraductal Carcinoma Nuclear Grade Operative Surgical Procedures Outcome Pathologist Pathology Pathway interactions Patients Phenotype Process Quality of life Radiation therapy Recurrence Reproducibility Research Simple mastectomy System Translating Uncertainty United States Vermont Woman base breast cancer diagnosis breast surgery clinical application design high risk hormone therapy improved irradiation malignant breast neoplasm novel novel strategies outcome forecast prognostic screening treatment strategy

项目摘要

Every year, over 50,000 women in the United States are diagnosed with the non-lethal form of breast cancer known as ductal carcinoma in situ (DCIS). When a diagnosis of DCIS is confirmed on biopsy, most women are treated with partial mastectomy and breast irradiation or elect total mastectomy as a means to avoid radiation therapy. Newer approaches to treatment for DCIS have suggested that surgical excision and observation, with or without endocrine therapy, may be an alternative for small volume, low grade DCIS. However, as a general rule, the underlying biology of DCIS is just beginning to be considered in the context of treating DCIS. A substantial body of basic science regarding the underlying molecular alterations present in DCIS suggests there are two major pathways of progression constituting an indolent and aggressive form of DCIS. The goal of this proposal Is to translate the research data on the numerous molecular genetic abnormalities present In DCIS into a pathology classification algorithm based on a restricted set of molecular, immunohistochemical, or morphologic features that will reliably Identify low grade and high grade progression pathways in DCIS. This would promote conservative treatment strategies for a subset of women with favorable prognosis DCIS and reduce the potential unfavorable consequences of over treating indolent breast disease.

在美国，每年有50,000多名妇女被诊断出患有非致命性乳腺癌称为导管原位癌(DCIS)。当活检确诊为DCIS时，大多数女性都是接受乳房部分切除和乳房放射治疗或选择全乳房切除作为避免辐射的手段心理治疗。治疗DCIS的新方法建议手术切除和观察，或不进行内分泌治疗，可能是小体积、低级别DCIS的一种替代方案。然而，作为一名将军，根据规则，DCIS的潜在生物学才刚刚开始在治疗DCIS的背景下被考虑。一个大量关于DCIS潜在分子改变的基础科学研究表明有两条主要的进展途径构成了一种惰性和侵略性的DCIS形式。的目标是这项提议是为了将关于存在于基于一组受限的分子、免疫组织化学或可以可靠地识别DCIS中低级别和高级别进展途径的形态特征。这将促进部分预后良好的DCIS和DCIS女性的保守治疗策略减少过度治疗惰性乳房疾病的潜在不良后果。